Table 1 Open in new tab Univariate and...

Chemotherapy or Radiation (n = 61 [in 56 patients])	OS (Univariate)	OS (Multivariate)^†
Increase of TGR (cc/day)	26.97 (5.16–140.89)	3.91	<0.001**	14.66 (2.72–78.99)	3.13	0.009**
Baseline tumor volume (cc)	1.07 (1.03–1.11)	3.54	<0.001**	1.09 (1.02–1.17)	2.64	0.02*
MGMT promoter methylation	0.65 (0.31–1.36)	−1.14	0.25	0.38 (0.16–0.90)	−2.19	0.048*
Number of recurrences (2^nd vs 1^st)	3.18 (1.57–6.45)	3.20	0.001**	3.15 (1.05–9.45)	2.05	0.048*
RT	0.41 (0.19–0.88)	−2.29	0.02*	0.53 (0.20–1.41)	−1.27	0.20
Chemotherapy (n = 44 [in 42 patients])	OS (Univariate)	OS (Multivariate)^†
Hazard Ratio (95% CI)	Z score	P value	Hazard Ratio (95% CI)	Z score	P value
Increase of TGR (cc/day)	28.28 (4.90–163.35)	3.74	<0.001**	13.28 (2.35–75.21)	2.92	0.01*
Baseline tumor volume (cc)	1.06 (1.02–1.10)	2.81	0.005**	1.08 (1.01–1.16)	2.27	0.04*
MGMT promoter methylation	0.59 (0.24–1.44)	−1.15	0.25	0.34 (0.11–1.05)	−1.87	0.08
Number of recurrences (2^nd vs 1^st)	3.33 (1.39–7.94)	2.71	0.007**	2.71 (0.68–10.79)	1.42	0.16

Chemotherapy or Radiation
(n = 61 [in 56 patients])

OS (Univariate)

OS (Multivariate)^†

Hazard Ratio (95% CI)

Z score

P value

Hazard Ratio (95% CI)

Z score

P value

Increase of TGR (cc/day)

26.97 (5.16–140.89)

3.91

<0.001**

14.66 (2.72–78.99)

3.13

0.009**

Baseline tumor volume (cc)

1.07 (1.03–1.11)

3.54

<0.001**

1.09 (1.02–1.17)

2.64

0.02*

MGMT promoter methylation

0.65 (0.31–1.36)

−1.14

0.25

0.38 (0.16–0.90)

−2.19

0.048*

Number of recurrences (2^nd vs 1^st)

3.18 (1.57–6.45)

3.20

0.001**

3.15 (1.05–9.45)

2.05

0.048*

0.41 (0.19–0.88)

−2.29

0.02*

0.53 (0.20–1.41)

−1.27

0.20

Chemotherapy
(n = 44 [in 42 patients])

OS (Univariate)

OS (Multivariate)^†

Hazard Ratio (95% CI)

Z score

P value

Hazard Ratio (95% CI)

Z score

P value

Increase of TGR (cc/day)

28.28 (4.90–163.35)

3.74

<0.001**

13.28 (2.35–75.21)

2.92

0.01*

Baseline tumor volume (cc)

1.06 (1.02–1.10)

2.81

0.005**

1.08 (1.01–1.16)

2.27

0.04*

MGMT promoter methylation

0.59 (0.24–1.44)

−1.15

0.25

0.34 (0.11–1.05)

−1.87

0.08

Number of recurrences (2^nd vs 1^st)

3.33 (1.39–7.94)

2.71

0.007**

2.71 (0.68–10.79)

1.42

0.16

Chemotherapy or Radiation (n = 61 [in 56 patients])	OS (Univariate)	OS (Multivariate)^†
Increase of TGR (cc/day)	26.97 (5.16–140.89)	3.91	<0.001**	14.66 (2.72–78.99)	3.13	0.009**
Baseline tumor volume (cc)	1.07 (1.03–1.11)	3.54	<0.001**	1.09 (1.02–1.17)	2.64	0.02*
MGMT promoter methylation	0.65 (0.31–1.36)	−1.14	0.25	0.38 (0.16–0.90)	−2.19	0.048*
Number of recurrences (2^nd vs 1^st)	3.18 (1.57–6.45)	3.20	0.001**	3.15 (1.05–9.45)	2.05	0.048*
RT	0.41 (0.19–0.88)	−2.29	0.02*	0.53 (0.20–1.41)	−1.27	0.20
Chemotherapy (n = 44 [in 42 patients])	OS (Univariate)	OS (Multivariate)^†
Hazard Ratio (95% CI)	Z score	P value	Hazard Ratio (95% CI)	Z score	P value
Increase of TGR (cc/day)	28.28 (4.90–163.35)	3.74	<0.001**	13.28 (2.35–75.21)	2.92	0.01*
Baseline tumor volume (cc)	1.06 (1.02–1.10)	2.81	0.005**	1.08 (1.01–1.16)	2.27	0.04*
MGMT promoter methylation	0.59 (0.24–1.44)	−1.15	0.25	0.34 (0.11–1.05)	−1.87	0.08
Number of recurrences (2^nd vs 1^st)	3.33 (1.39–7.94)	2.71	0.007**	2.71 (0.68–10.79)	1.42	0.16

Table 1

Open in new tab

Univariate and Multivariate Cox Regression Analysis of OS in all 61 cases with chemotherapy or radiation and 44 cases with chemotherapy

Chemotherapy or Radiation (n = 61 [in 56 patients])	OS (Univariate)			OS (Multivariate)^†
Chemotherapy or Radiation (n = 61 [in 56 patients])	Hazard Ratio (95% CI)	Z score	P value	Hazard Ratio (95% CI)	Z score	P value
Increase of TGR (cc/day)	26.97 (5.16–140.89)	3.91	<0.001**	14.66 (2.72–78.99)	3.13	0.009**
Baseline tumor volume (cc)	1.07 (1.03–1.11)	3.54	<0.001**	1.09 (1.02–1.17)	2.64	0.02*
MGMT promoter methylation	0.65 (0.31–1.36)	−1.14	0.25	0.38 (0.16–0.90)	−2.19	0.048*
Number of recurrences (2^nd vs 1^st)	3.18 (1.57–6.45)	3.20	0.001**	3.15 (1.05–9.45)	2.05	0.048*
RT	0.41 (0.19–0.88)	−2.29	0.02*	0.53 (0.20–1.41)	−1.27	0.20
Chemotherapy (n = 44 [in 42 patients])	OS (Univariate)			OS (Multivariate)^†
Chemotherapy (n = 44 [in 42 patients])	Hazard Ratio (95% CI)	Z score	P value	Hazard Ratio (95% CI)	Z score	P value
Increase of TGR (cc/day)	28.28 (4.90–163.35)	3.74	<0.001**	13.28 (2.35–75.21)	2.92	0.01*
Baseline tumor volume (cc)	1.06 (1.02–1.10)	2.81	0.005**	1.08 (1.01–1.16)	2.27	0.04*
MGMT promoter methylation	0.59 (0.24–1.44)	−1.15	0.25	0.34 (0.11–1.05)	−1.87	0.08
Number of recurrences (2^nd vs 1^st)	3.33 (1.39–7.94)	2.71	0.007**	2.71 (0.68–10.79)	1.42	0.16

Chemotherapy or Radiation (n = 61 [in 56 patients])	OS (Univariate)			OS (Multivariate)^†
Chemotherapy or Radiation (n = 61 [in 56 patients])	Hazard Ratio (95% CI)	Z score	P value	Hazard Ratio (95% CI)	Z score	P value
Increase of TGR (cc/day)	26.97 (5.16–140.89)	3.91	<0.001**	14.66 (2.72–78.99)	3.13	0.009**
Baseline tumor volume (cc)	1.07 (1.03–1.11)	3.54	<0.001**	1.09 (1.02–1.17)	2.64	0.02*
MGMT promoter methylation	0.65 (0.31–1.36)	−1.14	0.25	0.38 (0.16–0.90)	−2.19	0.048*
Number of recurrences (2^nd vs 1^st)	3.18 (1.57–6.45)	3.20	0.001**	3.15 (1.05–9.45)	2.05	0.048*
RT	0.41 (0.19–0.88)	−2.29	0.02*	0.53 (0.20–1.41)	−1.27	0.20
Chemotherapy (n = 44 [in 42 patients])	OS (Univariate)			OS (Multivariate)^†
Chemotherapy (n = 44 [in 42 patients])	Hazard Ratio (95% CI)	Z score	P value	Hazard Ratio (95% CI)	Z score	P value
Increase of TGR (cc/day)	28.28 (4.90–163.35)	3.74	<0.001**	13.28 (2.35–75.21)	2.92	0.01*
Baseline tumor volume (cc)	1.06 (1.02–1.10)	2.81	0.005**	1.08 (1.01–1.16)	2.27	0.04*
MGMT promoter methylation	0.59 (0.24–1.44)	−1.15	0.25	0.34 (0.11–1.05)	−1.87	0.08
Number of recurrences (2^nd vs 1^st)	3.33 (1.39–7.94)	2.71	0.007**	2.71 (0.68–10.79)	1.42	0.16

^†Controlling for age and sex. *P < 0.05, **P < 0.01.

OS, overall survival; RT, radiation therapy; TGR, tumor growth rate; MGMT, O⁶-methylguanine-DNA methyltransferase.

This Feature Is Available To Subscribers Only